Cargando…
A gene expression signature distinguishes innate response and resistance to proteasome inhibitors in multiple myeloma
Extensive interindividual variation in response to chemotherapy is a major stumbling block in achieving desirable efficacy in the treatment of cancers, including multiple myeloma (MM). In this study, our goal was to develop a gene expression signature that predicts response specific to proteasome in...
Autores principales: | Mitra, A K, Harding, T, Mukherjee, U K, Jang, J S, Li, Y, HongZheng, R, Jen, J, Sonneveld, P, Kumar, S, Kuehl, W M, Rajkumar, V, Van Ness, B |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5520403/ https://www.ncbi.nlm.nih.gov/pubmed/28665416 http://dx.doi.org/10.1038/bcj.2017.56 |
Ejemplares similares
-
Molecular signatures of multiple myeloma progression through single cell RNA-Seq
por: Jang, Jin Sung, et al.
Publicado: (2019) -
Proteasome Inhibitors for the Treatment of Multiple Myeloma
por: Ito, Shigeki
Publicado: (2020) -
New proteasome inhibitors in the treatment of multiple myeloma
por: Hungria, Vania Tietsche de Moraes, et al.
Publicado: (2019) -
Pulmonary Nocardiosis in a Multiple Myeloma Patient Treated with Proteasome Inhibitors
por: Mendonca, Nikolai P., et al.
Publicado: (2016) -
Paradoxical resistance of multiple myeloma to proteasome inhibitors by decreased levels of 19S proteasomal subunits
por: Acosta-Alvear, Diego, et al.
Publicado: (2015)